ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells

Journal of Cellular Physiology

Volumn 226, Issue 2, 2011, Pages 375-384

  Sarkar, Siddik ^a   Mazumdar, Abhijit ^b   Dash, Rupesh ^c   Sarkar, Devanand ^c,d   Fisher, Paul B ^c,d   Mandal, Mahitosh ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY   (India)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CASPASE 3; CASPASE 7; CYCLIN D1; CYCLIN E; CYTOSKELETON PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; VANDETANIB; VASCULOTROPIN RECEPTOR;

ANCHORAGE INDEPENDENT GROWTH; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL INVASION; CELL MIGRATION; CELL VIABILITY; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSKELETON; DOWN REGULATION; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTOSKELETON; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; PACLITAXEL; PIPERIDINES; QUINAZOLINES;

EID: 78649651308     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22343     Document Type: Article

References (40)

1. Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS, Blamey RW, Robertson JF, Nicholson RI, Ellis IO. 2004. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 91: 1532-1542.
2. Baselga J, Gianni L, Geyer C, Perez EA, Riva A, Jackisch C. 2004. Future options with trastuzumab for primary systemic and adjuvant therapy. Semin Oncol 31: 51-57.
3. Benhar M, Engelberg D, Levitzki A. 2002. Cisplatin-induced activation of the EGF receptor. Oncogene 21: 8723-8731.
4. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B. 2005. EGFR gene amplification in breast cancer: Correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 18: 1027-1033.
5. Bortner DM, Rosenberg MP. 1997. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol 17: 453-459.
6. Chou TC, Talalay P. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
7. Ciardiello F, Caputo R, Damiano V, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G. 2003. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9: 1546-1556.
8. Davidson NG. 1996. Single-agent paclitaxel as first-line treatment of metastatic breast cancer: The British experience. Semin Oncol 23: 6-10.
9. DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D II, Thor AD. 2005. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 23: 1152-1160.
10. DiMilla PA, Stone JA, Quinn JA, Albelda SM, Lauffenburger DA. 1993. Maximal migration of human smooth muscle cells on fibronectin and type IV collagen occurs at an intermediate attachment strength. J Cell Biol 122: 729-737.
11. Duband JL, Dufour S, Yamada SS, Yamada KM, Thiery JP. 1991. Neural crest cell locomotion induced by antibodies to beta 1 integrins. A tool for studying the roles of substratum molecular avidity and density in migration. J Cell Sci 98: 517-532.
12. Ferrara N, Houck K, Jakeman L, Leung DW. 1992. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13: 18-32.
13. Frederick B, Gustafson D, Bianco C, Ciardiello F, Dimery I, Raben D. 2006. ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. Int J Radiat Oncol Biol Phys 64: 33-37.
14. Garcia-Martin E, Pizarro RM, Martinez C, Gutierrez-Martin Y, Perez G, Jover R, Agundez JA. 2006. Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8. Pharmacogenomics 7: 575-585.
15. Grunwald V, Hidalgo M. 2003. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 95: 851-867.
16. Huh JE, Kang KS, Chae C, Kim HM, Ahn KS, Kim SH. 2004. Roles of p38 and JNK mitogen-activated protein kinase pathways during cantharidin-induced apoptosis in U937 cells. Biochem Pharmacol 67: 1811-1818.
17. Hynes NE, Lane HA. 2005. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354.
18. Kurebayashi J, Otsuki T, Kunisue H, Mikami Y, Tanaka K, Yamamoto S, Sonoo H. 1999. Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn J Cancer Res 90: 977-981.
19. Lauffenburger DA, Horwitz AF. 1996. Cell migration: A physically integrated molecular process. Cell 84: 359-369.
20. Liang CC, Park AY, Guan JL. 2007. In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2: 329-333.
21. Magne N, Fischel JL, Tiffon C, Formento P, Dubreuil A, Renee N, Formento JL, Francoual M, Ciccolini J, Etienne MC, Milano G. 2003. Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil. Br J Cancer 89: 585-592.
22. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM. 2005. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23: 4265-4274.
23. Mendelsohn J, Baselga J. 2003. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787-2799.
24. Mendelsohn J, Fan Z. 1997. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 89: 341-343.
25. Mi Y, Lou L. 2007. ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein. Br J Cancer 97: 934-940.
26. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. 1994. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576-579.
27. Morelli MP, Cascone T, Troiani T, De Vita F, Orditura M, Laus G, Eckhardt SG, Pepe S, Tortora G, Ciardiello F. 2005. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol 16: iv61-iv68.
28. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Raju SM, Smulson ME, Yamin TT, Yu VL, Miller DK. 1995. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37-43.
29. Perez EA. 1998. Paclitaxel in breast cancer. Oncologist 3: 373-389.
30. Ryden L, Stendahl M, Jonsson H, Emdin S, Bengtsson NO, Landberg G. 2005. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response. Breast Cancer Res Treat 89: 135-143.
31. Sarkar S, Mandal M. 2009. Growth factor receptors and apoptosis regulators: Signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer. Breast Cancer Basic Clin Res 9: 47.
32. Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher PB, Mandal M. 2010. ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol Ther 8: 9.
33. Sgambato A, Camerini A, Pani G, Cangiano R, Faraglia B, Bianchino G, De Bari B, Galeotti T, Cittadini A. 2003. Increased expression of cyclin E is associated with an increased resistance to doxorubicin in rat fibroblasts. Br J Cancer 88: 1956-1962.
34. Sumitomo M, Asano T, Asakuma J, Horiguchi A, Hayakawa M. 2004. ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway. Clin Cancer Res 10: 794-801.
35. Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, Nesland JM. 2002. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 196: 17-25.
36. Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G. 2004. AEE788: A dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 64: 4931-4941.
37. Van de Water B, Kruidering M, Nagelkerke JF. 1996. F-actin disorganization in apoptotic cell death of cultured rat renal proximal tubular cells. Am J Physiol 270: F593-F603.
38. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS. 2001. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res 61: 5090-5101.
39. Weidner N, Semple JP, Welch WR, Folkman J. 1991. Tumor angiogenesis and metastasis-Correlation in invasive breast carcinoma. N Engl J Med 324: 1-8.
40. Yu Q, Geng Y, Sicinski P. 2001. Specific protection against breast cancers by cyclin D1 ablation. Nature 411: 1017-1021.